<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Prognosis after myocardial infarction</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Prognosis after myocardial infarction</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Prognosis after myocardial infarction</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Peter WF Wilson, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Joseph S Alpert, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael Simons, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jeffrey A Breall, MD, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Pamela S Douglas, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Bernard J Gersh, MB, ChB, DPhil, FRCP, MACC</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Patricia A Pellikka, MD, FACC, FAHA, FASE</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Juan Carlos Kaski, DSc, MD, DM (Hons), FRCP, FESC, FACC, FAHA</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Christopher P Cannon, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Allan S Jaffe, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Todd F Dardas, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 17, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Survivors of a first acute myocardial infarction (MI) face a substantial risk of further cardiovascular events, including death, recurrent MI, heart failure, arrhythmias, angina, and stroke. Patients (and family members) often ask what their future holds; thus, information regarding prognosis after MI is necessary for patient care.</p><p>This topic discusses prognosis after MI secondary to obstructive coronary artery disease with or without plaque rupture. Prognosis after MI in the setting of less common entities such as MI with no obstructive coronary atherosclerosis, spontaneous coronary artery dissection, or stress (takotsubo) cardiomyopathy are presented separately. (See  <a class="medical medical_review" href="/z/d/html/97665.html" rel="external">"Spontaneous coronary artery dissection", section on 'Sequelae'</a> and  <a class="medical medical_review" href="/z/d/html/104151.html" rel="external">"Management and prognosis of stress (takotsubo) cardiomyopathy", section on 'Prognosis'</a> and  <a class="medical medical_review" href="/z/d/html/100408.html" rel="external">"Myocardial infarction or ischemia with no obstructive coronary atherosclerosis"</a>.)</p><p>The outcomes discussed in this topic, such as mortality, are presented using pooled data. However, the prognosis may vary widely between individuals, according to the presence or absence of risk factors present before the MI. These risk factors are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/77.html" rel="external">"Risk factors for adverse outcomes after non-ST elevation acute coronary syndromes"</a> and  <a class="medical medical_review" href="/z/d/html/88759.html" rel="external">"Risk factors for adverse outcomes after ST-elevation myocardial infarction"</a>.)</p><p>The prognosis of young patients after MI is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/50.html" rel="external">"Coronary artery disease and myocardial infarction in young people", section on 'Prognosis after MI'</a>.)</p><p>The likelihood of subsequent events presented here are rough estimates. For most patients with MI, clinicians should risk stratify them using validated risk prediction models. This process is described in detail separately. (See  <a class="medical medical_review" href="/z/d/html/78.html" rel="external">"Risk stratification after acute ST-elevation myocardial infarction"</a> and  <a class="medical medical_review" href="/z/d/html/76.html" rel="external">"Risk stratification after non-ST elevation acute coronary syndrome"</a>.)</p><p>The discussion of sudden cardiac death following MI is found elsewhere. (See  <a class="medical medical_review" href="/z/d/html/1052.html" rel="external">"Incidence of and risk stratification for sudden cardiac death after myocardial infarction"</a> and <a class="local">'Adverse nonfatal outcomes'</a> below.)</p><p class="headingAnchor" id="H2"><span class="h1">SHORT-TERM OUTCOMES</span><span class="headingEndMark"> — </span>Reported outcomes, and in particular, mortality, will vary based on the population studied. While many of the reports come from randomized trials, we consider outcomes reported from registries to be a better gauge. Registries usually include broad populations, whereas trial participation is often limited by inclusion/exclusion criteria.</p><p class="headingAnchor" id="H632888902"><span class="h2">Mortality</span><span class="headingEndMark"> — </span>Across the broad spectrum of patients with acute MI, short-term (in-hospital or 30-day) mortality has been decreasing over the past 30 years, concomitantly with the increasing use of reperfusion strategies and proven preventative therapies such as beta blockers, <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a>, and statins [<a href="#rid1">1-9</a>]. (See  <a class="medical medical_review" href="/z/d/html/80.html" rel="external">"Acute ST-elevation myocardial infarction: Selecting a reperfusion strategy"</a> and  <a class="medical medical_review" href="/z/d/html/1505.html" rel="external">"Prevention of cardiovascular disease events in those with established disease (secondary prevention) or at very high risk"</a>.)</p><p>The 30-day mortality after all acute coronary syndromes (ST-elevation myocardial infarction [STEMI], non-ST-elevation myocardial infarction [NSTEMI], and unstable angina) is probably in the 2 to 3 percent range, but likely around 5 percent if patients with unstable angina are not included [<a href="#rid10">10</a>]. (See  <a class="medical medical_review" href="/z/d/html/66.html" rel="external">"Overview of the acute management of ST-elevation myocardial infarction"</a>.)</p><p>In a report that evaluated the interval 1987 to 2002, the 28-day case fatality fell from 5.3 to 3.8 percent [<a href="#rid11">11</a>]. A similar trend was noted in an analysis of data on 2.5 million patients from the National Registry of Myocardial Infarction in which in-hospital mortality after an acute MI declined from 10.4 percent in 1994 to 6.3 percent in 2006 [<a href="#rid7">7</a>].</p><p>Increasing age appears to predict increasing mortality [<a href="#rid12">12</a>].</p><p class="headingAnchor" id="H3"><span class="h3">STEMI</span><span class="headingEndMark"> — </span>The 30-day mortality rate of patients with STEMI is between 2.5 and 10 percent in reports [<a href="#rid10">10,13-17</a>].</p><p>Both in-hospital and 30-day mortality rates after STEMI have been lower in clinical trials compared to registries and reports in patients not in clinical trials. This has been explained by enrollment of a lower risk population and better adherence to proven therapies in the former. Among patients with STEMI enrolled in trials, approximate in-hospital or 30-day mortality rates were 13 percent with medical therapy alone, 6 to 7 percent with optimal fibrinolytic therapy [<a href="#rid18">18,19</a>], and as low as 3 to 5 percent with primary percutaneous coronary intervention (PCI) when performed within two hours of chest pain onset [<a href="#rid15">15,20,21</a>]. (See  <a class="medical medical_review" href="/z/d/html/72.html" rel="external">"Primary percutaneous coronary intervention in acute ST elevation myocardial infarction: Determinants of outcome", section on 'Time from hospital arrival (door-to-balloon time)'</a> and  <a class="medical medical_review" href="/z/d/html/55.html" rel="external">"Acute ST-elevation myocardial infarction: The use of fibrinolytic therapy"</a>.)</p><p>Somewhat higher in-hospital and 30-day mortality rates after STEMI have been described in patients not enrolled in clinical trials and cared for during a similar time period. The reported in-hospital mortality has been reported between 7 and 9.7 percent and the 30-day mortality between 11.1 and 14 percent for these patients [<a href="#rid16">16,22,23</a>]. A number of factors could contribute to this difference, including patient selection, less frequent use of appropriate therapies, and data collection before trials supporting the value of primary PCI [<a href="#rid16">16,22-24</a>].</p><p>More contemporary reports of patients not enrolled in trials have documented a continued decline in mortality in STEMI patients [<a href="#rid13">13,14,25</a>]. For example, outcomes were presented in a 2012 report of 6707 STEMI patients in four French nationwide registries conducted five years apart (1995, 2000, 2005, and 2010) [<a href="#rid26">26</a>]. The following findings were noted:</p><p class="bulletIndent1"><span class="glyph">●</span>There were significant decreases in crude 30-day mortality (from 13.7 to 4.4 percent) and mortality standardized to 2010 population characteristics (from 11.3 to 4.4 percent). These declines were seen irrespective of the type of reperfusion (fibrinolysis or PCI) and in patients who were not reperfused.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Time from symptom onset to hospital admission decreased, with a shorter time from onset to first call, and broader use of mobile intensive care units.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>During this time, the average age fell and the prevalence of most risk factors increased.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The use of reperfusion therapy increased from 50 to 75 percent, driven mostly by an increase of the use of PCI, as did the use of recommended preventative medical therapies.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Within the STEMI population assessed in these registries, the relative proportion of older patients decreased, and the proportion of younger patients increased. These registry data suggest that future strategies aimed at further reducing acute MI incidence and mortality will need to specifically target prevention in younger patients. (See  <a class="medical medical_review" href="/z/d/html/1505.html" rel="external">"Prevention of cardiovascular disease events in those with established disease (secondary prevention) or at very high risk"</a>.)</p><p></p><p>Some patients with acute STEMI present without modifiable cardiovascular risk factors such as smoking, hypertension, diabetes, or dyslipidemia (see  <a class="medical medical_review" href="/z/d/html/88759.html" rel="external">"Risk factors for adverse outcomes after ST-elevation myocardial infarction", section on 'Factors present before MI'</a>). The SWEDEHEART registry was used to analyze 30-day survival in adults with and without these traditional risk factors using dichotomous definitions for elevated cholesterol, diabetes mellitus, smoking, and blood pressure. Patients without these risk factors fared worse than persons with at least one risk factor [<a href="#rid27">27</a>]. All-cause mortality at 30 days was 11.3 percent in those without and 7.9 percent in those with at least one traditional risk factor. Key determinants for a worse prognosis were longer time from symptom onset to cardiac intensive care unit or emergency department admission, longer time for symptom onset to angiography, and occurrence of cardiogenic shock during the hospital stay. The authors found that evidence-based interventions at the time of a STEMI hospitalization were the key determinants of 30-day survival. This study has significant limitations. For example, patients without traditional outpatient risk factors using dichotomous definitions experienced greater mortality risk than would be expected. In addition, the authors used dichotomous risk factor definitions that appear to be derived from administrative data information and are probably much less accurate than what is in detailed clinical notes or in the epidemiology literature. The risk factor definitions used in the paper are not optimal or standard; for example, family history was not included. Finally, those individuals without risk factors might have included patients without atherosclerotic plaque rupture as the underlying mechanism (eg, spontaneous coronary artery dissection, microvascular disease, or stress cardiomyopathy). These individuals can represent up to 2 percent of acute STEMI patients, and their prognosis is likely different. Despite its limitations, this paper is important as it highlights limitations to our ability to prognosticate well in the individual patient.</p><p class="headingAnchor" id="H4"><span class="h3">NSTEMI</span><span class="headingEndMark"> — </span>This category includes a wide spectrum of patients, leading to wide variation in mortality. Among patients with a non-ST-elevation acute coronary syndrome (NSTEACS), in-hospital or 30-day mortality has been about 2 percent in major clinical trials, lower than that seen in STEMI [<a href="#rid28">28,29</a>]. Although an early invasive strategy is now performed in most patients, because of reductions in recurrent MI or rehospitalization for an ACS, mortality rates in randomized trials were not significantly reduced in-hospital (or at six months) by this strategy [<a href="#rid28">28,29</a>].</p><p>The following studies include the range of findings for patients not enrolled in randomized controlled clinical trials:</p><p class="bulletIndent1"><span class="glyph">●</span>In the GRACE registry of over 16,000 patients from 14 countries seen between 2001 and 2007, the in-hospital mortality was 3.3 percent with NSTEACS [<a href="#rid30">30</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the French registry of 1645 patients with NSTEMI managed with an invasive strategy in 2005, the in-hospital mortality was 2.0 percent [<a href="#rid31">31</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the Worcester (Massachusetts, United States) Heart Attack Study, the hospital and 30-day post-admission case fatality rates for 2005 were 9.5 and 14.0 percent, respectively [<a href="#rid32">32</a>].</p><p></p><p class="headingAnchor" id="H5"><span class="h3">STEMI versus NSTEMI</span><span class="headingEndMark"> — </span>While initial studies suggested that short-term mortality is lower in patients with NSTEMI (2 to 4 percent) compared with patients with STEMI (2.5 to 10 percent) treated with primary PCI within two hours of hospital arrival [<a href="#rid10">10,20,21,23,28,29,33</a>], other studies show no significant differences. An analysis of 5420 patients in the Kyoto registry showed no differences in both short- and long-term mortality in STEMI compared with NSTEMI patients [<a href="#rid34">34</a>]. Similarly, no differences were observed in a prospective study of 2151 patients in 56 medical centers in France [<a href="#rid35">35</a>].</p><p>Better short-term outcomes for patients with NSTEMI have also been noted in other studies (eg, in-hospital mortality 5 to 7 percent compared with 7.0 to 9.3 percent with STEMI in the GRACE and Euro Heart registries) [<a href="#rid22">22,23,28</a>].</p><p class="headingAnchor" id="H12574987"><span class="h2">Adverse nonfatal outcomes</span><span class="headingEndMark"> — </span>Besides death, other patient-important outcomes include stroke, recurrent MI, heart failure, and major bleeding. In the GRACE registry of patients with NSTEACS discussed above, the rates of in-hospital heart failure or shock, MI, major bleeding, or stroke were 10, 2.4, 1.8, and 0.5 percent, respectively [<a href="#rid30">30</a>]. In the HORIZONS AMI randomized trial, the rate of stroke was around 1 percent and the rate of reinfarction was about 2 percent at 30 days [<a href="#rid15">15</a>].</p><p class="headingAnchor" id="H632888839"><span class="h2">Early rehospitalization</span><span class="headingEndMark"> — </span>The rate of rehospitalization within 30 days after acute MI is reported to range between 17 and 25 percent [<a href="#rid36">36,37</a>]. In a single-community (Olmsted County, Minnesota, United States) study of 3010 patients who were hospitalized for a first-ever MI (31 percent STEMI) between 1987 and 2010, rehospitalization within 30 days occurred in about 19 percent [<a href="#rid38">38</a>]. Of these, 30 percent were and 43 percent were not related to the incident event. Diabetes, chronic obstructive pulmonary disease, anemia, higher Killip class  (<a class="graphic graphic_table graphicRef65592" href="/z/d/graphic/65592.html" rel="external">table 1</a>), longer length of stay during the index hospitalization, and a complication of angiography or reperfusion or revascularization were associated with increased rehospitalization risk.</p><p>Additionally, the rate of rehospitalization at 30 days appears to be higher in females. (See  <a class="medical medical_review" href="/z/d/html/77.html" rel="external">"Risk factors for adverse outcomes after non-ST elevation acute coronary syndromes", section on 'Sex'</a>.) In a study of 42,518 individuals aged 18 to 64 years, the 30-day all-cause readmission rate was higher for females (15.5 versus 9.7 percent; p = 0.01) [<a href="#rid39">39</a>]. This increase in risk persisted after adjustment but was of a smaller magnitude (hazard ratio, 1.22; 95% CI 1.15-1.3).</p><p class="headingAnchor" id="H4275873030"><span class="h2">COVID-19 patients</span><span class="headingEndMark"> — </span>Acute myocardial injury with troponin elevation occurs in approximately 20 percent of adults hospitalized with coronavirus disease 2019 (COVID-19) infection [<a href="#rid40">40</a>]. Higher troponin levels during hospitalization have been reported to adversely affect survival in COVID-19-infected patients [<a href="#rid41">41,42</a>]. Additional determinants of mortality following acute myocardial injury include diabetes, hypertension, and underlying cardiovascular disease (CVD) [<a href="#rid43">43</a>]. This issue is discussed in greater detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/127533.html" rel="external">"COVID-19: Myocardial infarction and other coronary artery disease issues", section on 'Prognosis'</a>.)</p><p class="headingAnchor" id="H17"><span class="h1">LONG-TERM OUTCOMES</span></p><p class="headingAnchor" id="H18"><span class="h2">Mortality</span><span class="headingEndMark"> — </span>− Similar to short-term outcomes, long-term mortality rates after MI have declined over time, which correlates with improvements in reperfusion and preventative strategies. In an analysis of 23 published studies in which follow-up was completed prior to 1980, the death rate was about 28 percent at five years [<a href="#rid44">44</a>]. A report had a five-year death rate of about 21 percent in patients treated between 1989 and 1993 [<a href="#rid45">45</a>].</p><p>A 2022 report described the post-MI prognosis for 100,601 patients who survived an MI between 2005 to 2012 and had an outpatient risk factor assessment after hospital discharge [<a href="#rid46">46</a>]. Over a mean of 4.0 years of follow-up there were 31,622 all-cause deaths and 12,901 CVD deaths. At the postdischarge visit, older age, current smoking, atrial fibrillation, heart failure, peripheral artery disease, and lower body mass index were associated with worse prognosis, while statin therapy, hypertension medication, higher estimated glomerular filtration rate, and higher body mass index were associated with a lower risk of fatal outcomes.</p><p>The PEGASUS-TIMI 54 trial evaluated effects over three-year follow-up for <a class="drug drug_general" data-topicid="16784" href="/z/d/drug information/16784.html" rel="external">ticagrelor</a> added to <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> therapy in persons who had survived an MI that occurred one to three years earlier (see  <a class="medical medical_review" href="/z/d/html/1572.html" rel="external">"Long-term antiplatelet therapy after coronary artery stenting in stable patients", section on 'Treatment for longer than 12 months'</a>). There was a 15 percent reduction in CVD death (2.9 versus 3.4 percent) [<a href="#rid47">47</a>]. Approximately 1 percent of the aspirin-only participants experienced TIMI major bleeding, and ticagrelor increased that risk more than twofold. Benefit for ticagrelor was observed in both diabetic and nondiabetic trial participants [<a href="#rid48">48</a>].</p><p>In contrast to the short-term outcomes, which are worse with STEMI, long-term outcomes have been similar or worse with NSTEMI [<a href="#rid2">2,28,49-53</a>]. The largest direct comparison comes from the GUSTO-IIb trial performed in the early 1990s of 12,142 patients with STEMI, NSTEMI (using only creatine kinase MB fraction, not troponins, for diagnosis), or unstable angina [<a href="#rid49">49</a>]. The mortality rate at 30 days was lower with NSTEMI than STEMI (3.8 versus 6.1 percent). In contrast, the mortality at one year was similar (8.8 for NSTEMI versus 9.6 percent for STEMI). However, outcomes from patients with NSTEMI managed more recently were lower in the ISAR REACT 4 trial, in which mortality at one year was about 4.4 percent. (See  <a class="medical medical_review" href="/z/d/html/93.html" rel="external">"Anticoagulant therapy in non-ST elevation acute coronary syndromes", section on 'Unfractionated heparin compared with bivalirudin'</a>.)</p><p>In a community-based observational study of almost 6000 first MIs over a 23-year period, patients with an NSTEMI (compared to those with STEMI) had higher two-year mortality (20 versus 11 percent) [<a href="#rid2">2</a>]. Other registry reports suggest that, at one and two years, the cumulative mortality for NSTEMI exceeds that of STEMI patients. In the OPERA registry, cardiovascular outcomes were evaluated in 2151 consecutive patients (71 percent STEMI) with confirmed MI during 2002 and 2003 [<a href="#rid35">35</a>]. The STEMI patients were treated with primary percutaneous coronary intervention (PCI) (71 percent) or fibrinolytic therapy (29 percent), while PCI was performed in 52 percent of NSTEMI patients. In-hospital mortality was not different for both groups (4.6 versus 4.3 percent), while the one-year post-discharge mortality was higher with NSTEMI (8.2 versus 5.0 percent). In a report for the Worcester (Massachusetts, United States) Heart Attack Study, the one-year post-discharge case fatality rates in 2005 for patients with STEMI and NSTEMI were 8.4 and 18.7 percent, respectively [<a href="#rid16">16</a>].</p><p>Further evidence suggesting worse long-term outcomes with NSTEMI comes from a comparison of two studies that evaluated outcomes separately. A French registry evaluated outcomes in 1645 patients with NSTEMI managed with an invasive strategy during 2005 and found that mortality at three years was approximately 20 percent, with about half the deaths due to cardiovascular causes [<a href="#rid31">31</a>]. However, mortality at three years was around 6 to 7 percent in the HORIZONS AMI trial of patients with STEMI who underwent primary PCI [<a href="#rid54">54</a>].</p><p>The similar or worse long-term prognosis in NSTEMI is in part related to more than a 50 percent prevalence of multivessel disease in affected patients and to a greater likelihood of residual ischemia [<a href="#rid49">49,55,56</a>], indicating that in these patients, a significant amount of myocardium often remains at risk.</p><p class="headingAnchor" id="H102808993"><span class="h3">Sudden cardiac death</span><span class="headingEndMark"> — </span>The broad discussion of sudden cardiac death (SCD) and sudden cardiac arrest is found elsewhere. (See  <a class="medical medical_review" href="/z/d/html/963.html" rel="external">"Overview of sudden cardiac arrest and sudden cardiac death"</a> and  <a class="medical medical_review" href="/z/d/html/974.html" rel="external">"Pathophysiology and etiology of sudden cardiac arrest"</a> and  <a class="medical medical_review" href="/z/d/html/1052.html" rel="external">"Incidence of and risk stratification for sudden cardiac death after myocardial infarction"</a>.)</p><p>The incidence of SCD after acute MI is the same with STEMI and NSTEMI [<a href="#rid1">1,57</a>]. Among patients who have had an MI and are followed for about four years, approximately one-half of sudden deaths occur in the first year and one-quarter in the first three months [<a href="#rid58">58,59</a>]. The risk is markedly increased in patients with a left ventricular ejection fraction ≤35 percent. (See  <a class="medical medical_review" href="/z/d/html/1052.html" rel="external">"Incidence of and risk stratification for sudden cardiac death after myocardial infarction", section on 'Incidence of SCD'</a>.)</p><p class="headingAnchor" id="H21"><span class="h2">Adverse nonfatal outcomes</span><span class="headingEndMark"> — </span>While most patients are concerned about survival, many ask questions about other clinically important outcomes:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Angina</strong> − A study of nearly 2000 patients who sustained an MI in 2003 or 2004 found that angina occurred in nearly 20 percent as early as one year and the determinants were younger age, male sex, not being a White person, prior angina, angina during the hospital stay, smoking continuation, depression, and coronary artery bypass graft surgery history [<a href="#rid60">60</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Recurrent MI and stroke</strong> – In the HORIZONS AMI trial, the risk of reinfarction or stroke at three years was approximately 6 to 7 and 1.5 to 2 percent, respectively [<a href="#rid54">54</a>].</p><p></p><p>Risk after an MI is not the same for all patients and prognosis can be estimated in the outpatient setting for survivors. The GRACE Study investigated subjects at the time of an acute coronary syndrome event and the key variables were age, heart rate, systolic pressure, creatinine, congestive heart failure, cardiac arrest at admission, ST segment deviation, and cardiac enzymes [<a href="#rid61">61</a>]. Other investigators have evaluated prognosis when the baseline evaluation is more than several months after a vascular disease event. For example, a report based on the two-year post-MI experience of 49,689 REACH Registry participants from around the world has shown that recurrent cardiovascular (CVD) disease and CVD death can be predicted with a simple algorithm. The core variables in the REACH prediction model were age, male sex, presence of peripheral vascular disease or cerebrovascular disease, diabetes, smoking, low body mass index, history of atrial fibrillation, heart failure, history of a CVD event in the past year, and favorable effects on risk were seen for statins and <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> [<a href="#rid62">62</a>].</p><p>Similarly, in the SMART Study, after 4.7 years of follow-up for 5788 Dutch adults with coronary disease, peripheral arterial disease, or cerebrovascular disease at baseline, the key predictor variables for recurrent vascular disease were age, male sex, smoking, systolic pressure, total cholesterol, high density lipoprotein-cholesterol, high sensitivity C-reactive protein, estimated glomerular filtration rate, and years since first vascular event [<a href="#rid63">63</a>].</p><p class="headingAnchor" id="H1773967824"><span class="h1">SOCIAL AND ENVIRONMENTAL FACTORS AND PROGNOSIS AFTER MYOCARDIAL INFARCTION</span><span class="headingEndMark"> — </span>Prognosis following an MI is affected by social and environmental factors:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Environmental factors</strong> – In an analysis across 567 cities in 27 countries, extreme ambient temperatures, either very hot (99<sup>th</sup> percentile) or very cold (1<sup>st</sup> percentile), were associated with a greater risk of mortality in persons known to have ischemic heart disease [<a href="#rid64">64</a>]. In a meta-analysis of 42 studies, greater exposure to air particles &lt;2.5 micrometers in diameter was associated with increased risk of death and recurrent acute MI in persons with ischemic heart disease [<a href="#rid65">65</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Socioeconomic factors</strong> – Socioeconomic disadvantage has also been associated with greater long-term mortality for persons experiencing an MI prior to age 50 years, and the impact of social disadvantage was an independent risk factor for adverse outcomes [<a href="#rid66">66</a>].</p><p></p><p class="headingAnchor" id="H10105262"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/16327.html" rel="external">"Patient education: Heart attack recovery (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/z/d/html/3430.html" rel="external">"Patient education: Heart attack recovery (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H27"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span>Survivors of a myocardial infarction (MI) face a substantial excess risk of further cardiovascular events, including an increase in mortality. However, the prognosis for an individual varies markedly according to the presence or absence of adverse risk factors. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Short- and long-term death rates following MI have fallen substantially in the past few decades with improvements in medical care, particularly the widespread use of reperfusion techniques and the adjunctive use of multiple medical therapies. (See <a class="local">'Short-term outcomes'</a> above and <a class="local">'Mortality'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The current 30-day mortality after all acute coronary syndromes (ST-elevation myocardial infarction [STEMI], non-ST-elevation myocardial infarction [NSTEMI], and unstable angina) is probably in the 2 to 3 percent range, but likely around 5 percent if patients with unstable angina are not included. (See <a class="local">'Mortality'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Short-term mortality is lower in patients with NSTEMI (2 to 4 percent) compared to patients with STEMI (3 to 8 percent) treated with primary percutaneous coronary intervention within two hours of hospital arrival. (See <a class="local">'STEMI versus NSTEMI'</a> above.) Long-term mortality is similar or worse with NSTEMI. At one year, mortality is around 5 to 9 percent. (See <a class="local">'Mortality'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Rosamond WD, Chambless LE, Folsom AR, et al. Trends in the incidence of myocardial infarction and in mortality due to coronary heart disease, 1987 to 1994. N Engl J Med 1998; 339:861.</a></li><li><a class="nounderline abstract_t">Furman MI, Dauerman HL, Goldberg RJ, et al. Twenty-two year (1975 to 1997) trends in the incidence, in-hospital and long-term case fatality rates from initial Q-wave and non-Q-wave myocardial infarction: a multi-hospital, community-wide perspective. J Am Coll Cardiol 2001; 37:1571.</a></li><li><a class="nounderline abstract_t">Rogers WJ, Canto JG, Lambrew CT, et al. Temporal trends in the treatment of over 1.5 million patients with myocardial infarction in the US from 1990 through 1999: the National Registry of Myocardial Infarction 1, 2 and 3. J Am Coll Cardiol 2000; 36:2056.</a></li><li><a class="nounderline abstract_t">Heidenreich PA, McClellan M. Trends in treatment and outcomes for acute myocardial infarction: 1975-1995. Am J Med 2001; 110:165.</a></li><li><a class="nounderline abstract_t">Fang J, Alderman MH. Dissociation of hospitalization and mortality trends for myocardial infarction in the United States from 1988 to 1997. Am J Med 2002; 113:208.</a></li><li><a class="nounderline abstract_t">Velagaleti RS, Pencina MJ, Murabito JM, et al. Long-term trends in the incidence of heart failure after myocardial infarction. Circulation 2008; 118:2057.</a></li><li><a class="nounderline abstract_t">Rogers WJ, Frederick PD, Stoehr E, et al. Trends in presenting characteristics and hospital mortality among patients with ST elevation and non-ST elevation myocardial infarction in the National Registry of Myocardial Infarction from 1990 to 2006. Am Heart J 2008; 156:1026.</a></li><li><a class="nounderline abstract_t">Gibson CM, Pride YB, Frederick PD, et al. Trends in reperfusion strategies, door-to-needle and door-to-balloon times, and in-hospital mortality among patients with ST-segment elevation myocardial infarction enrolled in the National Registry of Myocardial Infarction from 1990 to 2006. Am Heart J 2008; 156:1035.</a></li><li><a class="nounderline abstract_t">Krumholz HM, Wang Y, Chen J, et al. Reduction in acute myocardial infarction mortality in the United States: risk-standardized mortality rates from 1995-2006. JAMA 2009; 302:767.</a></li><li><a class="nounderline abstract_t">Roe MT, Messenger JC, Weintraub WS, et al. Treatments, trends, and outcomes of acute myocardial infarction and percutaneous coronary intervention. J Am Coll Cardiol 2010; 56:254.</a></li><li><a class="nounderline abstract_t">Myerson M, Coady S, Taylor H, et al. Declining severity of myocardial infarction from 1987 to 2002: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation 2009; 119:503.</a></li><li><a class="nounderline abstract_t">Smilowitz NR, Mahajan AM, Roe MT, et al. Mortality of Myocardial Infarction by Sex, Age, and Obstructive Coronary Artery Disease Status in the ACTION Registry-GWTG (Acute Coronary Treatment and Intervention Outcomes Network Registry-Get With the Guidelines). Circ Cardiovasc Qual Outcomes 2017; 10:e003443.</a></li><li><a class="nounderline abstract_t">Rosamond WD, Chambless LE, Heiss G, et al. Twenty-two-year trends in incidence of myocardial infarction, coronary heart disease mortality, and case fatality in 4 US communities, 1987-2008. Circulation 2012; 125:1848.</a></li><li><a class="nounderline abstract_t">Jernberg T, Johanson P, Held C, et al. Association between adoption of evidence-based treatment and survival for patients with ST-elevation myocardial infarction. JAMA 2011; 305:1677.</a></li><li><a class="nounderline abstract_t">Tobbia P, Brodie BR, Witzenbichler B, et al. Adverse event rates following primary PCI for STEMI at US and non-US hospitals: three-year analysis from the HORIZONS-AMI trial. EuroIntervention 2013; 8:1134.</a></li><li><a class="nounderline abstract_t">McManus DD, Gore J, Yarzebski J, et al. Recent trends in the incidence, treatment, and outcomes of patients with STEMI and NSTEMI. Am J Med 2011; 124:40.</a></li><li><a class="nounderline abstract_t">Bagai A, Lu D, Lucas J, et al. Temporal Trends in Utilization of Cardiac Therapies and Outcomes for Myocardial Infarction by Degree of Chronic Kidney Disease: A Report From the NCDR Chest Pain-MI Registry. J Am Heart Assoc 2018; 7:e010394.</a></li><li><a class="nounderline abstract_t">GUSTO investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993; 329:673.</a></li><li><a class="nounderline abstract_t">Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT-2) Investigators, Van De Werf F, Adgey J, et al. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. Lancet 1999; 354:716.</a></li><li><a class="nounderline abstract_t">Cannon CP, Gibson CM, Lambrew CT, et al. Relationship of symptom-onset-to-balloon time and door-to-balloon time with mortality in patients undergoing angioplasty for acute myocardial infarction. JAMA 2000; 283:2941.</a></li><li><a class="nounderline abstract_t">Stone GW, Grines CL, Cox DA, et al. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med 2002; 346:957.</a></li><li><a class="nounderline abstract_t">Steg PG, Goldberg RJ, Gore JM, et al. Baseline characteristics, management practices, and in-hospital outcomes of patients hospitalized with acute coronary syndromes in the Global Registry of Acute Coronary Events (GRACE). Am J Cardiol 2002; 90:358.</a></li><li><a class="nounderline abstract_t">Hasdai D, Behar S, Wallentin L, et al. A prospective survey of the characteristics, treatments and outcomes of patients with acute coronary syndromes in Europe and the Mediterranean basin; the Euro Heart Survey of Acute Coronary Syndromes (Euro Heart Survey ACS). Eur Heart J 2002; 23:1190.</a></li><li><a class="nounderline abstract_t">Bahit MC, Cannon CP, Antman EM, et al. Direct comparison of characteristics, treatment, and outcomes of patients enrolled versus patients not enrolled in a clinical trial at centers participating in the TIMI 9 Trial and TIMI 9 Registry. Am Heart J 2003; 145:109.</a></li><li><a class="nounderline abstract_t">Yeh RW, Sidney S, Chandra M, et al. Population trends in the incidence and outcomes of acute myocardial infarction. N Engl J Med 2010; 362:2155.</a></li><li><a class="nounderline abstract_t">Puymirat E, Simon T, Steg PG, et al. Association of changes in clinical characteristics and management with improvement in survival among patients with ST-elevation myocardial infarction. JAMA 2012; 308:998.</a></li><li><a class="nounderline abstract_t">Figtree GA, Vernon ST, Hadziosmanovic N, et al. Mortality in STEMI patients without standard modifiable risk factors: a sex-disaggregated analysis of SWEDEHEART registry data. Lancet 2021; 397:1085.</a></li><li><a class="nounderline abstract_t">Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. FRagmin and Fast Revascularisation during InStability in Coronary artery disease Investigators. Lancet 1999; 354:708.</a></li><li><a class="nounderline abstract_t">Cannon CP, Weintraub WS, Demopoulos LA, et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med 2001; 344:1879.</a></li><li><a class="nounderline abstract_t">Brieger D, Fox KA, Fitzgerald G, et al. Predicting freedom from clinical events in non-ST-elevation acute coronary syndromes: the Global Registry of Acute Coronary Events. Heart 2009; 95:888.</a></li><li><a class="nounderline abstract_t">Puymirat E, Taldir G, Aissaoui N, et al. Use of invasive strategy in non-ST-segment elevation myocardial infarction is a major determinant of improved long-term survival: FAST-MI (French Registry of Acute Coronary Syndrome). JACC Cardiovasc Interv 2012; 5:893.</a></li><li><a class="nounderline abstract_t">Floyd KC, Yarzebski J, Spencer FA, et al. A 30-year perspective (1975-2005) into the changing landscape of patients hospitalized with initial acute myocardial infarction: Worcester Heart Attack Study. Circ Cardiovasc Qual Outcomes 2009; 2:88.</a></li><li class="breakAll">http://www.outcomes-umassmed.org/grace/.</li><li><a class="nounderline abstract_t">Yaku H, Shiomi H, Morimoto T, et al. Comparison of short- and long-term mortality between ST-segment elevation and non-ST-segment elevation myocardial infarction. J Am Coll Cardiol 2016; 67.</a></li><li><a class="nounderline abstract_t">Montalescot G, Dallongeville J, Van Belle E, et al. STEMI and NSTEMI: are they so different? 1 year outcomes in acute myocardial infarction as defined by the ESC/ACC definition (the OPERA registry). Eur Heart J 2007; 28:1409.</a></li><li><a class="nounderline abstract_t">Joynt KE, Orav EJ, Jha AK. Thirty-day readmission rates for Medicare beneficiaries by race and site of care. JAMA 2011; 305:675.</a></li><li><a class="nounderline abstract_t">Curtis JP, Schreiner G, Wang Y, et al. All-cause readmission and repeat revascularization after percutaneous coronary intervention in a cohort of medicare patients. J Am Coll Cardiol 2009; 54:903.</a></li><li><a class="nounderline abstract_t">Dunlay SM, Weston SA, Killian JM, et al. Thirty-day rehospitalizations after acute myocardial infarction: a cohort study. Ann Intern Med 2012; 157:11.</a></li><li><a class="nounderline abstract_t">Dreyer RP, Ranasinghe I, Wang Y, et al. Sex Differences in the Rate, Timing, and Principal Diagnoses of 30-Day Readmissions in Younger Patients with Acute Myocardial Infarction. Circulation 2015; 132:158.</a></li><li><a class="nounderline abstract_t">Bavishi C, Bonow RO, Trivedi V, et al. Special Article - Acute myocardial injury in patients hospitalized with COVID-19 infection: A review. Prog Cardiovasc Dis 2020; 63:682.</a></li><li><a class="nounderline abstract_t">Shi S, Qin M, Cai Y, et al. Characteristics and clinical significance of myocardial injury in patients with severe coronavirus disease 2019. Eur Heart J 2020; 41:2070.</a></li><li><a class="nounderline abstract_t">Bonow RO, Fonarow GC, O'Gara PT, Yancy CW. Association of Coronavirus Disease 2019 (COVID-19) With Myocardial Injury and Mortality. JAMA Cardiol 2020; 5:751.</a></li><li><a class="nounderline abstract_t">de Almeida-Pititto B, Dualib PM, Zajdenverg L, et al. Severity and mortality of COVID 19 in patients with diabetes, hypertension and cardiovascular disease: a meta-analysis. Diabetol Metab Syndr 2020; 12:75.</a></li><li><a class="nounderline abstract_t">Law MR, Watt HC, Wald NJ. The underlying risk of death after myocardial infarction in the absence of treatment. Arch Intern Med 2002; 162:2405.</a></li><li><a class="nounderline abstract_t">Bata IR, Gregor RD, Wolf HK, Brownell B. Trends in five-year survival of patients discharged after acute myocardial infarction. Can J Cardiol 2006; 22:399.</a></li><li><a class="nounderline abstract_t">Lu B, Posner D, Vassy JL, et al. Prediction of Cardiovascular and All-Cause Mortality After Myocardial Infarction in US Veterans. Am J Cardiol 2022; 169:10.</a></li><li><a class="nounderline abstract_t">Bonaca MP, Bhatt DL, Cohen M, et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med 2015; 372:1791.</a></li><li><a class="nounderline abstract_t">Bhatt DL, Bonaca MP, Bansilal S, et al. Reduction in Ischemic Events With Ticagrelor in Diabetic Patients With Prior Myocardial Infarction in PEGASUS-TIMI 54. J Am Coll Cardiol 2016; 67:2732.</a></li><li><a class="nounderline abstract_t">Armstrong PW, Fu Y, Chang WC, et al. Acute coronary syndromes in the GUSTO-IIb trial: prognostic insights and impact of recurrent ischemia. The GUSTO-IIb Investigators. Circulation 1998; 98:1860.</a></li><li><a class="nounderline abstract_t">Behar S, Haim M, Hod H, et al. Long-term prognosis of patients after a Q wave compared with a non-Q wave first acute myocardial infarction. Data from the SPRINT Registry. Eur Heart J 1996; 17:1532.</a></li><li><a class="nounderline abstract_t">Haim M, Behar S, Boyko V, et al. The prognosis of a first Q-wave versus non-Q-wave myocardial infarction in the reperfusion era. Am J Med 2000; 108:381.</a></li><li><a class="nounderline abstract_t">Yan AT, Tan M, Fitchett D, et al. One-year outcome of patients after acute coronary syndromes (from the Canadian Acute Coronary Syndromes Registry). Am J Cardiol 2004; 94:25.</a></li><li><a class="nounderline abstract_t">Singh M, Reeder GS, Jacobsen SJ, et al. Scores for post-myocardial infarction risk stratification in the community. Circulation 2002; 106:2309.</a></li><li><a class="nounderline abstract_t">Stone GW, Witzenbichler B, Guagliumi G, et al. Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial. Lancet 2011; 377:2193.</a></li><li><a class="nounderline abstract_t">Liebson PR, Klein LW. The non-Q wave myocardial infarction revisited: 10 years later. Prog Cardiovasc Dis 1997; 39:399.</a></li><li><a class="nounderline abstract_t">Wang CH, Cherng WJ, Hua CC, Hung MJ. Prognostic value of dobutamine echocardiography in patients after Q-wave or non-Q-wave acute myocardial infarction. Am J Cardiol 1998; 82:38.</a></li><li><a class="nounderline abstract_t">Kannel WB, Cupples LA, D'Agostino RB. Sudden death risk in overt coronary heart disease: the Framingham Study. Am Heart J 1987; 113:799.</a></li><li><a class="nounderline abstract_t">Marchioli R, Barzi F, Bomba E, et al. Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-Prevenzione. Circulation 2002; 105:1897.</a></li><li><a class="nounderline abstract_t">Torp-Pedersen C, Køber L. Effect of ACE inhibitor trandolapril on life expectancy of patients with reduced left-ventricular function after acute myocardial infarction. TRACE Study Group. Trandolapril Cardiac Evaluation. Lancet 1999; 354:9.</a></li><li><a class="nounderline abstract_t">Maddox TM, Reid KJ, Spertus JA, et al. Angina at 1 year after myocardial infarction: prevalence and associated findings. Arch Intern Med 2008; 168:1310.</a></li><li><a class="nounderline abstract_t">Eagle KA, Lim MJ, Dabbous OH, et al. A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry. JAMA 2004; 291:2727.</a></li><li><a class="nounderline abstract_t">Wilson PW, D'Agostino R Sr, Bhatt DL, et al. An international model to predict recurrent cardiovascular disease. Am J Med 2012; 125:695.</a></li><li><a class="nounderline abstract_t">Dorresteijn JA, Visseren FL, Wassink AM, et al. Development and validation of a prediction rule for recurrent vascular events based on a cohort study of patients with arterial disease: the SMART risk score. Heart 2013; 99:866.</a></li><li><a class="nounderline abstract_t">Alahmad B, Khraishah H, Royé D, et al. Associations Between Extreme Temperatures and Cardiovascular Cause-Specific Mortality: Results From 27 Countries. Circulation 2023; 147:35.</a></li><li><a class="nounderline abstract_t">Bhatnagar A. Cardiovascular Effects of Particulate Air Pollution. Annu Rev Med 2022; 73:393.</a></li><li><a class="nounderline abstract_t">Berman AN, Biery DW, Ginder C, et al. Association of Socioeconomic Disadvantage With Long-term Mortality After Myocardial Infarction: The Mass General Brigham YOUNG-MI Registry. JAMA Cardiol 2021; 6:880.</a></li></ol></div><div id="topicVersionRevision">Topic 1531 Version 33.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9744969" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Trends in the incidence of myocardial infarction and in mortality due to coronary heart disease, 1987 to 1994.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11345367" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Twenty-two year (1975 to 1997) trends in the incidence, in-hospital and long-term case fatality rates from initial Q-wave and non-Q-wave myocardial infarction: a multi-hospital, community-wide perspective.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11127441" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Temporal trends in the treatment of over 1.5 million patients with myocardial infarction in the US from 1990 through 1999: the National Registry of Myocardial Infarction 1, 2 and 3.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11182101" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Trends in treatment and outcomes for acute myocardial infarction: 1975-1995.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12208379" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Dissociation of hospitalization and mortality trends for myocardial infarction in the United States from 1988 to 1997.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18955667" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Long-term trends in the incidence of heart failure after myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19032996" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Trends in presenting characteristics and hospital mortality among patients with ST elevation and non-ST elevation myocardial infarction in the National Registry of Myocardial Infarction from 1990 to 2006.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19032997" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Trends in reperfusion strategies, door-to-needle and door-to-balloon times, and in-hospital mortality among patients with ST-segment elevation myocardial infarction enrolled in the National Registry of Myocardial Infarction from 1990 to 2006.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19690309" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Reduction in acute myocardial infarction mortality in the United States: risk-standardized mortality rates from 1995-2006.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20633817" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Treatments, trends, and outcomes of acute myocardial infarction and percutaneous coronary intervention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19153274" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Declining severity of myocardial infarction from 1987 to 2002: the Atherosclerosis Risk in Communities (ARIC) Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29246884" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Mortality of Myocardial Infarction by Sex, Age, and Obstructive Coronary Artery Disease Status in the ACTION Registry-GWTG (Acute Coronary Treatment and Intervention Outcomes Network Registry-Get With the Guidelines).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22420957" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Twenty-two-year trends in incidence of myocardial infarction, coronary heart disease mortality, and case fatality in 4 US communities, 1987-2008.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21521849" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Association between adoption of evidence-based treatment and survival for patients with ST-elevation myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23425539" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Adverse event rates following primary PCI for STEMI at US and non-US hospitals: three-year analysis from the HORIZONS-AMI trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21187184" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Recent trends in the incidence, treatment, and outcomes of patients with STEMI and NSTEMI.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30514137" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Temporal Trends in Utilization of Cardiac Therapies and Outcomes for Myocardial Infarction by Degree of Chronic Kidney Disease: A Report From the NCDR Chest Pain-MI Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8204123" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10475182" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10865271" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Relationship of symptom-onset-to-balloon time and door-to-balloon time with mortality in patients undergoing angioplasty for acute myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11919304" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12161222" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Baseline characteristics, management practices, and in-hospital outcomes of patients hospitalized with acute coronary syndromes in the Global Registry of Acute Coronary Events (GRACE).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12127921" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : A prospective survey of the characteristics, treatments and outcomes of patients with acute coronary syndromes in Europe and the Mediterranean basin; the Euro Heart Survey of Acute Coronary Syndromes (Euro Heart Survey ACS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12514662" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Direct comparison of characteristics, treatment, and outcomes of patients enrolled versus patients not enrolled in a clinical trial at centers participating in the TIMI 9 Trial and TIMI 9 Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20558366" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Population trends in the incidence and outcomes of acute myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22928184" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Association of changes in clinical characteristics and management with improvement in survival among patients with ST-elevation myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33711294" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Mortality in STEMI patients without standard modifiable risk factors: a sex-disaggregated analysis of SWEDEHEART registry data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10475181" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. FRagmin and Fast Revascularisation during InStability in Coronary artery disease Investigators.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11419424" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19246481" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Predicting freedom from clinical events in non-ST-elevation acute coronary syndromes: the Global Registry of Acute Coronary Events.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22995875" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Use of invasive strategy in non-ST-segment elevation myocardial infarction is a major determinant of improved long-term survival: FAST-MI (French Registry of Acute Coronary Syndrome).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20031820" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : A 30-year perspective (1975-2005) into the changing landscape of patients hospitalized with initial acute myocardial infarction: Worcester Heart Attack Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20031820" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : A 30-year perspective (1975-2005) into the changing landscape of patients hospitalized with initial acute myocardial infarction: Worcester Heart Attack Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Comparison of short- and long-term mortality between ST-segment elevation and non-ST-segment elevation myocardial infarction</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17412730" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : STEMI and NSTEMI: are they so different? 1 year outcomes in acute myocardial infarction as defined by the ESC/ACC definition (the OPERA registry).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21325183" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Thirty-day readmission rates for Medicare beneficiaries by race and site of care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19712799" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : All-cause readmission and repeat revascularization after percutaneous coronary intervention in a cohort of medicare patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22751756" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Thirty-day rehospitalizations after acute myocardial infarction: a cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26085455" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Sex Differences in the Rate, Timing, and Principal Diagnoses of 30-Day Readmissions in Younger Patients with Acute Myocardial Infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32512122" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Special Article - Acute myocardial injury in patients hospitalized with COVID-19 infection: A review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32391877" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Characteristics and clinical significance of myocardial injury in patients with severe coronavirus disease 2019.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32219362" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Association of Coronavirus Disease 2019 (COVID-19) With Myocardial Injury and Mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32874207" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Severity and mortality of COVID 19 in patients with diabetes, hypertension and cardiovascular disease: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12437397" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : The underlying risk of death after myocardial infarction in the absence of treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16639475" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Trends in five-year survival of patients discharged after acute myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35063273" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Prediction of Cardiovascular and All-Cause Mortality After Myocardial Infarction in US Veterans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25773268" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Long-term use of ticagrelor in patients with prior myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27046160" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Reduction in Ischemic Events With Ticagrelor in Diabetic Patients With Prior Myocardial Infarction in PEGASUS-TIMI 54.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9799205" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Acute coronary syndromes in the GUSTO-IIb trial: prognostic insights and impact of recurrent ischemia. The GUSTO-IIb Investigators.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8909910" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Long-term prognosis of patients after a Q wave compared with a non-Q wave first acute myocardial infarction. Data from the SPRINT Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10759094" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : The prognosis of a first Q-wave versus non-Q-wave myocardial infarction in the reperfusion era.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15219503" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : One-year outcome of patients after acute coronary syndromes (from the Canadian Acute Coronary Syndromes Registry).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12403659" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Scores for post-myocardial infarction risk stratification in the community.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21665265" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9122424" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : The non-Q wave myocardial infarction revisited: 10 years later.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9671006" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Prognostic value of dobutamine echocardiography in patients after Q-wave or non-Q-wave acute myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3825868" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Sudden death risk in overt coronary heart disease: the Framingham Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11997274" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-Prevenzione.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10406358" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Effect of ACE inhibitor trandolapril on life expectancy of patients with reduced left-ventricular function after acute myocardial infarction. TRACE Study Group. Trandolapril Cardiac Evaluation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18574088" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Angina at 1 year after myocardial infarction: prevalence and associated findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15187054" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22727237" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : An international model to predict recurrent cardiovascular disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23574971" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Development and validation of a prediction rule for recurrent vascular events based on a cohort study of patients with arterial disease: the SMART risk score.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36503273" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Associations Between Extreme Temperatures and Cardiovascular Cause-Specific Mortality: Results From 27 Countries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34644154" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Cardiovascular Effects of Particulate Air Pollution.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34009238" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Association of Socioeconomic Disadvantage With Long-term Mortality After Myocardial Infarction: The Mass General Brigham YOUNG-MI Registry.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
